Placeholder Banner

Administration’s Benefit Rule Threatens Access and Affordability of Prescription Medicines

May 7, 2020
Media Contact
Author-Profile-Andrew-Segerman

BIO’s Tom DiLenge, President of Advocacy, Law & Public Policy Division issued the following statement today after the Trump administration adopted a “Notice of Benefit and Payment Parameters for 2021” that allows health plans to block drug manufacturer discounts from helping to lower patients’ cost-sharing obligations:

“This decision by the Trump administration is truly baffling. At a time when insurance companies are enjoying high profits while patients are struggling financially, the administration has adopted a rule that will increase patients’ out-of-pocket drug costs, undermine access to necessary medications, and further pad insurance company profits. This misguided approach will ultimately jeopardize the health and well-being of patients and lead to increased spending on other, more costly medical services. The American people should be focused on staying healthy and financially secure during these difficult times, but this reckless regulatory change risks both.”


###
 

Discover More
BIO recognizes Governor Cooper’s leadership in biotechnology & innovation Today, the Biotechnology Innovation Organization awarded Roy Cooper, Governor of North Carolina, with its 2020 Governor of the Year Award. Governor Cooper was presented…
Event Highlighted Leadership in Vaccine Development and Regional Growth in Biotechnology Innovation Gaithersburg, MD (September 24, 2020) – Today, Maryland Governor Larry Hogan and Dr. Michelle McMurry-Heath, President & CEO of Biotechnology…
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the Trump administration moved forward with its threat to impose foreign price controls on medicines covered under…